# E6/E7 Similarity to Human Papillomavirus Prototypes and Performance of HPV Testing by Cobas 4800 HPV Test and Anyplex II HPV HR

**Authors:** Luani R. Godoy, Mariam El‐Zein, Piet Cools, Elizaveta Padalko, Bo Verberckmoes, Olivier Degomme, Heleen Vermandere, Laila Sara Arroyo Mühr, Milan S. Stosic, Eduardo L. Franco, Adhemar Longatto‐Filho, Vivian Alejandra Neira, Vivian Alejandra Neira, Sónia Dias, Ana Gama, Yasmin M. Guimarães, Tauana C. Dias, Rui Manuel Reis

PMC · DOI: 10.1002/jmv.70668 · Journal of Medical Virology · 2025-10-28

## TL;DR

This study examines how genetic variations in HPV types affect the performance of HPV tests used for cervical cancer screening.

## Contribution

The study reveals that sequence variation relative to HPV prototypes can influence test performance in HPV detection.

## Key findings

- Sequence variation in HPV-negative samples was higher than in HPV-positive samples for certain HPV types using cobas and Anyplex tests.
- For HPV45, sequence variation was higher in HPV-positive samples when tested with Anyplex.
- Mean sequence variation was similar between HPV-negative and HPV-positive samples for several HPV types using Anyplex.

## Abstract

Human papillomavirus (HPV) genotype classification relies on DNA sequence similarity to reference (prototype) sequences. Most HPV assays used for cervical cancer screening were clinically validated against European HPV prototypes. However, the impact of HPV sequence polymorphisms on test performance remains unexplored. We evaluated whether sequence variation in E6/E7 relative to HPV prototypes affects test performance by analyzing cervicovaginal samples from 990 women enrolled (2019‐2022) across Belgium, Portugal, Brazil and Ecuador. Samples were tested using cobas, Anyplex, and next‐generation sequencing (Ampliseq/Ion Torrent targeting E6/E7). Sequence variation was defined as the proportion of single nucleotide polymorphisms across E6/E7 relative to reference sequence. Sequence variation was, on average, higher in HPV‐negative than HPV‐positive samples for HPV16 (0.46% vs 0.13%) and HPV18 (0.44% vs 0.37%) using cobas. Similar patterns were observed with Anyplex (HPV16: 0.78% vs 0.13%, HPV33: 0.66% vs 0.40%, HPV58: 0.79% vs 0.53, and HPV66: 1.14% vs 0.25%). For HPV45, sequence variation was, on average, higher in HPV‐positive than HPV‐negative samples when tested with Anyplex (0.87% vs 0.43%). For HPV types 18, 31, 35, 39, 51, 52, 56, 59 and 68, the mean sequence variation was similar between HPV‐negative and HPV‐positive samples using Anyplex. Our findings show that sequence variation relative to prototypes may impact test performance.

## Linked entities

- **Diseases:** cervical cancer (MONDO:0002974)

## Full-text entities

- **Diseases:** cervical cancer (MESH:D002583)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human papillomavirus (species) [taxon 10566], Human papillomavirus 16 (serotype) [taxon 333760]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12560617/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12560617/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12560617/full.md

---
Source: https://tomesphere.com/paper/PMC12560617